Navigation Links
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
Date:5/27/2015

NEW YORK, May 27, 2015 /PRNewswire/ -- PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

The lupus therapeutics market is dominated by generics and GlaxoSmithKline's Benlysta is the only drug that has gained marketing approval for SLE in more than 50 years. Following Benlysta's launch, patients' uptake has remained low, but due to its associated high price-tag Benlysta has managed to grow the lupus market in terms of value and is currently the top-selling drug in this market, having generated approximately $265.6m in 2014 in the seven major markets. There is high R&D activity for the development of new therapies for lupus and seven promising biological therapies have the potential to enter the SLE and LN market during the 2012-2022 forecast period. The introduction of new biologic drugs will shape the future competitive landscape and drive growth in the SLE and LN markets.

Highlights

Key Questions Answered

- What was the impact of Benlysta on the lupus therapeutics market following its approval in 2011 and what is its future outlook in this market?
- What do physicians think about Rituxan following its unsuccessful Phase III trials in LN, and how will it be used off-label in lupus during the forecast period?
- What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in SLE and LN?
- What are the significant unmet needs in the SLE and LN markets?
- What are the remaining opportunities in the SLE and LN markets?

Key Findings

- The key drivers of growth for the SLE and LN markets are the increasing uptake of GlaxoSmithKline's Benlysta, the potential launch of new biologic drugs and the increasing number of prevalent cases of SLE and LN during the 2012-2022 forecast period.
- R&D strategies include the development of me-too and first-in-class therapies, partnerships and acquisitions, and the development of products for LN.
- The lupus therapeutics market is characterized by significant unmet needs. The most pressing unmet need is the development of new therapies that will offer potent clinical benefits, have a positive safety profile and increase the available treatment options for patients.

Scope

- Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Annualized SLE and LN therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SLE and LN therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
- Analysis of the current and future market competition in the global SLE and LN therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global SLE and LN therapeutics markets.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SLE and LN therapeutics markets in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global SLE and LN therapeutics markets from 2012-2022.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Read the full report: http://www.reportlinker.com/p02913189-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
4. PharmaPoint: Alzheimers Disease - China Drug Forecast and Market Analysis to 2022
5. PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022
6. PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022
7. PharmaPoint: Neuropathic Pain - Japan Drug Forecast and Market Analysis to 2022
8. PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023
9. PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023
10. PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023
11. PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... ... , ... Autism is a developmental disorder affecting more than 3.5 million Americans’ ... in 68 people have the disorder), chances are you know someone on the autism ... with autism methods of communication and tactics to interact with others. These options help ...
(Date:8/7/2018)... ... August 06, 2018 , ... Drs. Jonathan and ... MS using laser dentistry techniques. Using their BIOLASE WaterLase® dental laser, this modern ... REPAIR Perio™. , Affecting the lives of millions of Americans, gum disease can ...
(Date:8/7/2018)... ... August 07, 2018 , ... ... role of Sanarus Technologies President, effective immediately. Mr. Stark will lead all ... experience in medical device toward finding new and innovative ways to advance ...
Breaking Medicine Technology:
(Date:8/15/2018)... , ... August 15, 2018 , ... Today David Hyde ... Kickstarter. , Born out of a desire for confidence and comfort year-round, ... and body odor – even in the hottest, most humid of climates. , The ...
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro Health, LLC (“Gastro ... for healthcare executives Simon Frisch and Chris Weinstein, who have been appointed Senior ... roles at a time of tremendous growth for the group, which has increased ...
(Date:8/11/2018)... ... 2018 , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch ... outpost trip to deliver dental care in impoverished communities. Along with a team of ... his time to help deliver care to over 550 individuals in need. , This ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... not realize their implants have ruptured, according to cross-referenced data from The American ... and silicone gel implant rupture rates monitored by the FDA. As an MRI ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Kathy Coover and the company’s independent distributors, customers, and employees, the newly established ... of fundraising, exceeding the $2 million goal. 100 percent of the donations will ...
Breaking Medicine News(10 mins):